Trial Profile
A Phase 2 Randomized, Open-Label, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2024
Price :
$35
*
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Islatravir (Primary) ; Lenacapavir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 06 Mar 2024 Results assessing efficacy and safety of islatravir plus lenacapavir, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
- 06 Mar 2024 According to a Gilead Sciences media release, data from this study were presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI).
- 06 Mar 2024 Results presented in a Gilead Sciences Media Release.